Bioavailability of BMS-626529 in Healthy Subjects From Prototype Low Dose Extended Release Formulations (Part 1) and Prototype Extended Release Multi-particulate Formulations (Part 2) of BMS-663068 Relative to 600 mg Extended Release Tablet

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

August 3, 2015

Primary Completion Date

November 5, 2015

Study Completion Date

November 5, 2015

Conditions

Infection, Human Immunodeficiency Virus

Interventions

DRUG

BMS-663068

Trial Locations (1)

GSK Investigational Site, Nottingham